ASBP — Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 2
- Website: https://aspirebiolabs.com
Latest SEC filings for ASBP
- 10-Q — 2026-05-15
- 8-K — 2026-05-14
- 8-K — 2026-04-20
- 8-K/A — 2026-04-17
- 8-K — 2026-04-16
- 8-K — 2026-04-16
- 8-K — 2026-04-16
- 8-K — 2026-04-15
- S-1/A — 2026-04-10
- 10-K — 2026-03-30
Educational tool only — not investment advice.